Skip to main content

Advertisement

SpringerLink
Log in

The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia

  • Case Report
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Sorafenib has been shown to be active in AML patients with FLT3-ITD. However, the effect of sorafenib in AML patients with FLT-TKD has never been well determined. Moreover, acquisition of secondary FLT3 TKD mutations, mainly at D835 (D835F/H/V/Y), are recognized as the major mechanisms of resistance of AML patients with FLT3-ITD to sorafenib. It has been reported that sorafenib induced death of cells that expressed the FLT3-ITD or FLT3-D835G but not cells that expressed the FLT3-D835Y point mutant or wild-type FLT3 in vitro. Here, we report the successful complete remission induction by sorafenib monotherapy in a FLT3-D835Y-positive patient with refractory AML-M5 followed by allogeneic stem cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Nakao M, Yokota S, Iwai T et al (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911–1918

    CAS  PubMed  Google Scholar 

  2. Yamamoto Y, Kiyoi H, Nakano Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439

    Article  CAS  PubMed  Google Scholar 

  3. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113(4):983–988

    Article  CAS  PubMed  Google Scholar 

  4. Levis M, Small D (2003) FLT3: ITDoes matter in leukemia. Leukemia 17:1738–1752

    Article  CAS  PubMed  Google Scholar 

  5. Wilhelm SM, Carter C et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  CAS  PubMed  Google Scholar 

  6. Sammons SL, Pratz KW, Smith BD, Karp JE, Emadi A (2014) Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol. doi:10.1002/ajh.23782

    PubMed  PubMed Central  Google Scholar 

  7. Ravandi F, Arana Yi C, Cortes JE et al (2014) Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28(7):1543–1545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Serve H, Krug U, Wagner R et al (2013) Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 31(25):3110–3118

    Article  CAS  PubMed  Google Scholar 

  9. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY et al (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28:1856–1862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY (2012) Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 119(22):5133–5143

    Article  CAS  PubMed  Google Scholar 

  11. Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H (2013) Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res 19(20):5758–5768

    Article  CAS  PubMed  Google Scholar 

  12. Zhang W et al (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia[J]. J Natl Cancer Inst 100(3):184–198

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Provincial Special Program of Medical Science (BL2012005), and Jiangsu Province’s Key Medical Center (ZX201102).

Author information

Author notes

    Authors and Affiliations

    1. Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu province, People’s Republic of China

      Yanhua Yue, Song Jin, Ting Xu, Jin Zhou, Liang Ma, Hongjie Shen, Depei Wu, Suning Chen & Miao Miao

    2. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China

      Yanhua Yue, Song Jin, Ting Xu, Jin Zhou, Liang Ma, Hongjie Shen, Depei Wu, Suning Chen & Miao Miao

    Authors
    1. Yanhua Yue
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Song Jin
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Ting Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Jin Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Liang Ma
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Hongjie Shen
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Depei Wu
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Suning Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Miao Miao
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Miao Miao.

    Ethics declarations

    Conflicts of interest

    The authors declare no conflict of interest.

    Additional information

    Yanhua Yue and Song Jin are contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Yue, Y., Jin, S., Xu, T. et al. The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. Indian J Hematol Blood Transfus 32 (Suppl 1), 38–40 (2016). https://doi.org/10.1007/s12288-015-0586-2

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12288-015-0586-2

    Keywords

    Search

    Navigation